New immununotherapy shown to shrink glioblastomas in small trial
US researchers used immunotherapy to target two proteins commonly found in glioblastomas.
Delivering dual-targeted, immune-focused chimeric antigen receptor T-cell cancer therapy via a patient’s spinal fluid has been shown to reduce the size of glioblastomas in a small US trial.
MRI brain scans of all six patients enrolled in the phase I trial showed rapid tumour reductions occurring within a day or two of treatment, according to results published in Nature Medicine.
